Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170347 | 0.82 | PARP1 (0.51) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL20435417 | 0.78 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL2317275 | 0.74 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL20187523 | 0.74 | PARP1 (0.59) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL29563063 | 0.74 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL8404371 | 0.72 | PARP1 (0.43) | PARP1CHEK1PIM1RPS6KA3SMN1; SMN2 | |
| SCHEMBL13659505 | 0.70 | PARP1 (0.64) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL20435418 | 0.70 | PARP1 (0.50) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL19754917 | 0.70 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3PDPK1 | |
| SCHEMBL29967230 | 0.70 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| EP-0056637-A1 | 4(3H)-quinazolinone derivatives, process for production thereof and pharmaceutical compositions comprising said compounds | Ishikawa, Masayuki (JP) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | PARP1 3268/4885CHEK1 4467/4885PIM1 3738/4885 |
| US-20180215737-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF | HCRTR1, HCRTR2, NPY5R | PARP1 3285/4885CHEK1 3864/4885PIM1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.